Vaxxinity up as Parkinson's disease vaccine met early-stage study goal

Vaxxinity

22/06/2023 19:00

** Shares of biotech company Vaxxinity Inc  VAXX.O  up 6.7%
at $2.24
    ** Company says its investigational vaccine, UB-312, for
Parkinson's disease (PD) treatment met primary early-stage study
objective
    ** Part B of the trial tested two doses of UB-312 vs placebo
in 20 age-matched subjects with early PD
    ** The vaccine candidate was well-tolerated and developed
antibodies against a protein that plays a key role in PD
development and progression
    ** Including session moves, stock up 60% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))